Vladimir Vexler Biography and Net Worth



Vladimir Vexler is our Chief Scientific Officer.

Prior to joining Coherus in 2013, Dr. Vexler was Senior Research Leader, Biotherapeutics at Hoffman-La Roche, where he acted as Global scientific leader for nonclinical safety of biotherapeutics and chaired Roche pRED Global Biotherapeutics Safety Team. Prior to that, Dr. Vexler was Director, Translational Medicine at Facet Biotech and Protein Design Labs, where he established and led the Department of Translational Medicine and led biomarker support for several pre-IND and clinical programs including Zynbryta and Empliciti. From 1994 to 2004, he served in multiple positions in Pre-Clinical Development at Protein Design Labs. Dr. Vexler began his career as a post-doctoral fellow at the Department of Radiology at UCSF.

Dr. Vexler has numerous peer-review publications in mAb development for immune-mediated inflammatory diseases and cancer. He earned a Ph.D. in Biology from the Institute of Chemical Physics, Academy of Science in Moscow and a M.S., Chemistry/Enzymology from the Moscow State University.

How do I contact Vladimir Vexler?

The corporate mailing address for Dr. Vexler and other Coherus BioSciences executives is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. Coherus BioSciences can also be reached via phone at (650) 649-3530 and via email at [email protected]. Learn More on Vladimir Vexler's contact information.

Has Vladimir Vexler been buying or selling shares of Coherus BioSciences?

Vladimir Vexler has not been actively trading shares of Coherus BioSciences during the last quarter. Most recently, Vladimir Vexler sold 114,240 shares of the business's stock in a transaction on Tuesday, March 9th. The shares were sold at an average price of $16.25, for a transaction totalling $1,856,400.00. Learn More on Vladimir Vexler's trading history.

Who are Coherus BioSciences' active insiders?

Coherus BioSciences' insider roster includes James Healy (Director), Dennis Lanfear (CEO), McDavid Stilwell (CFO), and Vladimir Vexler (Insider). Learn More on Coherus BioSciences' active insiders.

Are insiders buying or selling shares of Coherus BioSciences?

In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 223,100 shares worth more than $450,662.00. The most recent insider tranaction occured on November, 22nd when CEO Dennis M Lanfear sold 223,100 shares worth more than $450,662.00. Insiders at Coherus BioSciences own 11.0% of the company. Learn More about insider trades at Coherus BioSciences.

Information on this page was last updated on 11/22/2023.

Vladimir Vexler Insider Trading History at Coherus BioSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2021Sell114,240$16.25$1,856,400.00View SEC Filing Icon  
12/10/2020Sell17,626$18.05$318,149.30View SEC Filing Icon  
See Full Table

Vladimir Vexler Buying and Selling Activity at Coherus BioSciences

This chart shows Vladimir Vexler's buying and selling at Coherus BioSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Coherus BioSciences Company Overview

Coherus BioSciences logo
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $2.49
Low: $2.41
High: $2.51

50 Day Range

MA: $2.39
Low: $2.02
High: $2.85

2 Week Range

Now: $2.49
Low: $1.43
High: $8.65

Volume

468,006 shs

Average Volume

4,329,399 shs

Market Capitalization

$280.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54